PI Industries Q1 FY27 Results Analysis: EBITDA Margin Compresses 577 bps, Pharma Losses Hit Rs.81.6 Cr (PIIND)

P I Industries Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 1,702.30 Cr (-10.43% YoY) and PAT growth of -38.95% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

PI Industries reported a weak Q1 with revenue declining 10.4% YoY and EBITDA margin contracting 577 bps to 21.69%, missing multiple management guidance targets. The pharma segment continues to deteriorate, with record losses of Rs.81.6 Cr, while core standalone agrochemicals maintained a 28.7% EBITDA margin. Sequential QoQ growth of 8.8% offers some hope, but full-year positive growth guidance looks challenging given the magnitude of the decline.

Key Investment Insights

Key Positives

• Revenue improved 8.8% QoQ to Rs.1,702.3 Cr, consistent with sequential improvement beginning Q4
• Standalone EBITDA margin at 28.69% versus consolidated 21.69%, reflecting core business profitability
• Gross margin declined only 69 bps YoY to 56.74%, indicating stable cost of materials ratio
• No exceptional items booked in Q1FY27, providing clean earnings comparison

Risk Factors

• Revenue declined 10.43% YoY, fifth consecutive quarter of YoY contraction
• EBITDA margin compressed 577 bps YoY to 21.69%, the weakest Q1 margin since FY25
• Pharma segment revenue fell 25.03% YoY to Rs.54.2 Cr, with segment loss widening to Rs.81.6 Cr (margin -150.55%)
• Employee costs grew 12.27% YoY while revenue declined, adding 310 bps margin headwind
• Effective tax rate of 24.11% exceeded management's 22-23% guided band
• FY27 positive revenue guidance appears challenged given 10.43% decline in Q1